Another drug that is part of the glitazone group is rosiglitazone (Avandia). This drug also helps to make cells more sensitive to insulin and thus reduces high blood sugar levels. Doctors are prescribing this drug for their patients, hoping that Avandia will help prevent or reduce signs/symptoms of lipodystrophy.
A team of doctors in Houston, Texas, reviewed data from their clinic on PHAs who had been given Avandia. The doctors reported results on nine PHAs (2 female, 7 male) who had the following profile:
Avandia was used at a dose ranging between 4 and 8 mg/day. After six months of using this drug, the medical team reported that four subjects experienced decreased fat wasting and/or fat redistribution. Controlled studies of Avandia are needed to find out about the long-term impact of this drug for the following reasons:
REFERENCES
1. Gouda HE, Khan A, Schwartz J, Cohen RI. Liver failure in a patient treated with long-term rosiglitazone therapy. American Journal of Medicine 2001;111(7):584-5.
2. Kramer D, Shapiro R, Adler A, et al. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 2001;50(11):1294-1300.
3. Werner AL and Travaglini MT. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 2001;21(9):1082-99.
4. Visnegarwala F and Maldonado MR. Use of the PPAR-g modulator rosiglitazone in normoglycemic patients with HIV lipodystrophy syndrome. Abstract 124 - 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 23-26 October 2001, Athens, Greece.
20011210
CATE12304
Copyright © 2001 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
